Is the c.3G>C mutation in the succinate dehydrogenase subunit D (SDHD) gene due to a founder effect in Chinese head and neck paraganglioma patients?

• Published in: The Laryngoscope 2011-08, Vol.121 (8), p.1760-1764
• Main Authors: Zha, Yang, Chen, Xing-ming, Lam, Ching-wan, Lee, Soo-chin, Tong, Sui-fan, Gao, Zhi-qiang
• Format: Article
• Language: English
• Subjects: Adult; Biological and medical sciences; China; Dehydrogenases; Female; Founder Effect; Genes; Genetics, Population; Germ-Line Mutation; haplotype; Haplotypes; Head and Neck Neoplasms - genetics; Humans; individual case-control study; Level of Evidence: 3b; Level of Evidence: 3b, individual case‐control study; Male; Medical sciences; Microsatellite Repeats; Middle Aged; Mutation; Neurology; Otorhinolaryngology. Stomatology; paraganglioma; Paraganglioma - genetics; Point Mutation; succinate dehydrogenase; Succinate Dehydrogenase - genetics; Tumors of the nervous system. Phacomatoses
• ISSN: 0023-852X; 1531-4995
• DOI: 10.1002/lary.21850

Objectives/Hypothesis: Three Chinese patients with head and neck paragangliomas have been reported to carry the c.3G>C mutation in the succinate dehydrogenase subunit D (SDHD) gene. In addition, in our hospital, two further patients were identified who have the same mutation. It is unclear whether the c.3G>C mutation in Chinese patients is a recurrent mutation or if it is due to a founder effect. We conducted haplotype analysis on these patients to answer this question. Study Design: Individual case‐control study. Methods: Germ‐line mutations were confirmed in the patients and their families examined in this study using direct sequencing. We also constructed and analyzed haplotypes in four Chinese families. Genotype frequencies were compared to the control group. Results: Three of four families shared the same haplotype, which rarely occurred in the control group. The last family shared a very short area on the physical map with the other three families. Conclusions: There is a founder effect in Chinese head and neck paraganglioma patients carrying the SDHD c.3G>C mutation.